We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Booster shot

12 May 2021 By Aimee Donnellan

Clayton, Dubilier & Rice is buying UDG Healthcare for $3.7 bln. It’s a way to profit from Big Pharma’s need to cut costs and outsource drug development. But a post-crisis share bounce means the price isn’t cheap, and high returns aren’t assured. Some savvy dealmaking may help.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)